RİCHARD HC LAİ, DEBORAH KİM, FLORİNA CONSTANTİNESCU
European Journal of Rheumatology - 2016;3(4):188-190
Belimumab was approved by the United States Food and Drug Administration in March 2011 as the first biological agent for treating active systemic lupus erythematosus (SLE). To the best of our knowledge, this is the first case report regarding a patient with SLE treated with belimumab who was diagnosed with central nervous system nocardiosis.
